gdc-0449 and Hemangiosarcoma

gdc-0449 has been researched along with Hemangiosarcoma* in 1 studies

Other Studies

1 other study(ies) available for gdc-0449 and Hemangiosarcoma

Article	Year
Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma. European journal of cancer (Oxford, England : 1990), 2021, Volume: 150 Topics: Adult; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Basal Cell; Compassionate Use Trials; Hemangiosarcoma; Humans; Immune Checkpoint Inhibitors; Male; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Pyridines; Skin Neoplasms; Treatment Outcome; Xeroderma Pigmentosum	2021

Article

Year

Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma.

European journal of cancer (Oxford, England : 1990), 2021, Volume: 150

Topics: Adult; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Basal Cell; Compassionate Use Trials; Hemangiosarcoma; Humans; Immune Checkpoint Inhibitors; Male; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Pyridines; Skin Neoplasms; Treatment Outcome; Xeroderma Pigmentosum

2021